Patient

Age (years), gender

Diagnosis

Date of diagnosis

Systemic treatment

Graft

1

32, female

ALL with CALM/AF10 transcript

December 2007

vincristine, daunorubicin, cyclophosphamide, methotrexate, cytarabine, L-asparaginase, prednisone

Yes (autograft)

2

14, male

Acute biphenotypic leukaemia

March 2001

daunorubicin, vincristine, L-asparaginase, methylprednisolone, cytarabine, cyclophosphamide
vincristine, methotrexate, cytarabine, L-asparaginase, cyclophosphamide, vindesine, daunorubicin, mercaptopurine (molecular residual disease)

No

3

45, male

ALL Philadelphie +

December 2005

vincristine, dexamethasone, imatinib, methotrexate, cytarabine
vincristine, methotrexate, L-asparaginase, dasatinib, nilotinib, donor lymphocyte infusion (molecular residual disease)

Yes (allograft)

4

58, female

ALL following chronic myeloid leukaemia

March 2010

hydroxyurea, imatinib, idarubicin, cytarabine,

No

ALL: Acute lymphoblastic leukemia.
Table 1: Patients’ clinical and systemic treatment features.